Transactions
5
Insider / GLOBUS MEDICAL INC
Norwalk Leslie V
Director at GLOBUS MEDICAL INC
- Company
- GLOBUS MEDICAL INC
- First filing on record
- November 21, 2025
- Latest trade on record
- May 14, 2026
- SEC filings
- EDGAR ↗
Norwalk Leslie V, Director at GLOBUS MEDICAL INC, has disclosed 5 transactions in CVS, GMED since November 21, 2025: 0 purchases (0 open-market buys) and 2 sales, worth about $824K at the reported prices. The latest was filed May 15, 2026, 1 day after the trade.
Open-market buys
0
Sales
2
Avg. disclosure lag
2.4d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Norwalk Leslie V made no purchases and 2 sales worth $558K, plus 3 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Norwalk Leslie V has traded 1 stock on record; the largest by dollars is GMED.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 5 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| A | Grant or award | 3 | 18,099 | $266K |
| S | Open-market sale | 2 | 6,000 | $558K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 3 | 0 | 1 · $202K |
| 2025 | 2 | 0 | 1 · $355K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| CVS | Other A | May 14, 2026 | May 15, 2026 | 1d | 1,447 | $97 | $141K | Form 4 ↗ | ||
| GMED | Other A | January 21, 2026 | January 23, 2026 | 2d | 15,000 | — | — | derivative | Form 4 ↗ | |
| GMED | Sell S | January 8, 2026 | January 12, 2026 | 4d | 2,000 | $101 | $202K | 10b5-1 plan | Form 4 ↗ | |
| GMED | Sell S | December 12, 2025 | December 16, 2025 | 4d | 4,000 | $89 | $355K | 10b5-1 plan | Form 4 ↗ | |
| CVS | Other A | November 20, 2025 | November 21, 2025 | 1d | 1,652 | $76 | $126K | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| May 15, 2026 | Form 4 | 0000064803-26-000070 | 1 | published | EDGAR ↗ |
| January 23, 2026 | Form 4 | 0001193125-26-021266 | 1 | published | EDGAR ↗ |
| January 12, 2026 | Form 4 | 0001193125-26-010697 | 1 | published | EDGAR ↗ |
| December 16, 2025 | Form 4 | 0001193125-25-320898 | 1 | published | EDGAR ↗ |
| November 21, 2025 | Form 4 | 0000064803-25-000064 | 1 | published | EDGAR ↗ |
Other insiders at GLOBUS MEDICAL INC
- Mahoney Michael F Chairman, President & CEO 30 rows
- KIRBY J SCOTT Director 20 rows
- Finucane Anne A. Director 18 rows
- AGUIRRE FERNANDO Director 13 rows
- Kline Kyle Senior Vice President, CFO 13 rows
- Huller Kelly EVP, GC, Corporate Secretary 10 rows
- Newman Brian Director 10 rows
- ROBBINS LARRY Director 10 rows
- Davidar David D Director 9 rows
- FARAH ROGER N Director 9 rows
Everyone on file, with contracts and lobbying under the company's name: GLOBUS MEDICAL INC.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Rule 10b5-1 trading plans The plan must be set up when the insider has no important non-public information.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 5 | 5 | November 21, 2025 | May 15, 2026 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.